The Potential Impact of Measuring Healthcare Quality on Pharmaceutical-Related Costs and Outcomes

Quality measurements in managed care allow purchasers of health care to distinguish between health plans. Existing measures (Health Plan Employer Data and Information Set goals) for treatment of dyslipidemia provide a limited snapshot about quality of care for members within commercial health plans. Newer evidence (ie, the Heart Protection Study) and consensus guidelines (the National Cholesterol Education Program) expand the definition of high-risk populations and emphasize pharmacotherapy in managing dyslipidemia. We believe that newer evidence and standards provide health plans with the best opportunity to accurately assess the quality of dyslipidemia care for their populations. We propose a broad framework that provides health plans with guidance on developing a new quality measure for dyslipidemia that focuses on pharmacotherapy.

show abstract

Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality

Nair

Saseen

2006

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Potential Impact of Measuring Healthcare Quality on Pharmaceutical-Related Costs and Outcomes

Cited by 1 publication

References 39 publications

Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality

Quality Assessment of Dyslipidemia in Managed Care: Current Best Evidence Should Be Used to Benchmark Quality

Contact Info

Product

Resources

About